Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide

Clinical Pharmacokinetics

Volumn 48, Issue 4, 2009, Pages 243-252

  Nave, Rdiger ^a  

^a Nycomed GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CICLESONIDE; CORTICOSTEROID; CYTOCHROME P450 3A4; DESISOBUTYRYL CICLESONIDE; DRUG METABOLITE; ERYTHROMYCIN; FLUTICASONE; KETOCONAZOLE; NORFLURANE; PROPELLANT; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ASTHMA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TISSUE LEVEL; HUMAN; LUNG PARENCHYMA; METERED DOSE INHALER; OROPHARYNX; PERSISTENT ASTHMA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TISSUE DISTRIBUTION;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS; ASTHMA; DRUG INTERACTIONS; HUMANS; LUNG; MOLECULAR STRUCTURE; OROPHARYNX; PREGNENEDIONES; PROTEIN BINDING;

EID: 66949133866     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200948040-00002     Document Type: Review

References (71)

1. Canonica GW. Treating asthma as an inflammatory disease. Chest 2006; 130 Suppl. 1: 21S-28S
2. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368 (9537): 780-93
3. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics - 2002. J Allergy Clin Immunol 2002; 110 (5 Suppl.): S141-219
4. Masoli M, Fabian D, Holt S, et al. Global burden of asthma [online]. Available from URL: http://www.ginasthma.com/download.asp?intId=29 [Accessed 2008 May 20]
5. Tattersfield AE, Knox AJ, Britton JR, et al. Asthma. Lancet 2002; 360 (9342): 1313-22
6. Braman SS. The global burden of asthma. Chest 2006; 130 (1 Suppl.): 4S-12S
7. Georgitis JW. The 1997 asthma management guidelines and therapeutic issues relating to the treatment of asthma. Chest 1999; 115: 210-7
8. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006; 148 (3): 245-54
9. Barnes PJ. Molecular mechanisms of corticosteroids in allergic diseases. Allergy 2001; 56 (10): 928-36
10. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002; 15: 35-50
11. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003; 112 (3): 469-78
12. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004; 126 (1): 213-9
13. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006; 100 (8): 1307-17
14. Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 1998; 102 (4 Pt 2): S36-51
15. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91 Suppl. A: 22-8
16. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 112 (3 Suppl.): S1-40
17. Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006; 28 (5): 1042-50
18. Rohatagi S, Rhodes GR, Chaikin P. Absolute oral versus inhaled bioavail-ability: significance for inhaled drugs with special reference to inhaled gluco-corticoids. J Clin Pharmacol 1999; 39 (7): 661-3
19. Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004; 44 (1): 37-47
20. Dietzel K, Engelstatter R, Keller A. Ciclesonide: an on-site activated steroid. Prog Respir Res 2001; 31: 91-3
21. Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther 2005; 19 (6): 404-12
22. Postma DS, Sevette C, Martinat Y, et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001; 17: 1083-8
23. Langdon CG, Adler M, Mehra S, et al. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 2005; 99 (10): 1275-85
24. Niphadkar P, Jagannath K, Joshi JM, et al. Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study. Clin Ther 2005; 27 (11): 1752-63
25. Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005; 60 (3): 330-7
26. Metzer EO, Derendorf H. The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide. Ann Allergy Asthma Immunol 2006; 97: 149-57
27. Berger WE. Ciclesonide: a closer look at its systemic and oropharyngeal safety profile. Curr Drug Saf 2006; 1: 265-70
28. 14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmaco-kinet 2004; 43 (7): 479-86
29. Nave R, Bethke TD, Seiberling M, et al. Pharmacokinetics and pharmaco-dynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects [abstract]. Eur Respir J 2002; 20 Suppl. 38: P749
30. 99m)Tc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100 (3): 375-84
31. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005; 61 (3): 203-208. 49-258
32. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005; 45 (2): 146-52
33. Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmcodynamics of ciclesonide. J Clin Pharmacol 2003; 43 (4): 365-78
34. Nave R, Gunawardena KA, Zech K, et al. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar. IntJ Clin Pharmacol Ther 2006; 44 (1): 1-7
35. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005; 12 (3): 201-9
36. Adcock IM, Gilbey T, Gelder CM, et al. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 1996; 154 (3 Pt 1): 771-82
37. Stoeck M, Riedel R, Hochhaus G, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther 2004; 309 (1): 249-58
38. Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 2007; 73 (10): 1657-64
39. Nonaka T, Nave R, McCrackenN, et al. Ciclesonide uptake and metabolism in human alveolar type IIepithelial cells (A549). BMC Pharmacology 2007; 7: 12
40. Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm Drug Dispos 2006; 27 (4): 197-207
41. Nave R, Fisher R, McCracken N. In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices. Respir Res 2007; 8: 65
42. Drollmann A, Watz H, Nave R, et al. In vivo metabolism of ciclesonide in the human lung [abstract]. Proc Am Thorac Soc 2006; 3: A75
43. Nave R, McCracken N. Metabolism of ciclesonide in the upper and lower airways: review of available data. J Asthma Allergy 2008; 1: 11-8
44. 14C-ciclesonide in hepatocytes from the mouse, rat, rabbit, dog, and human. Am J Ther 2007; 14 (3): 280-90
45. Peet CF, Enos T, Nave R, et al. Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet 2005; 30 (4): 275-86
46. Guo Z, Gu Z, Howell SR, et al. Ciclesonide disposition and metabolism: pharmacokinetics, metabolism, and excretion in the mouse, rat, rabbit, and dog. Am J Ther 2006; 13: 490-501
47. Minshall EM, Hogg JC, Hamid QA. Cytokine mRNA expression in asthma is not restricted to the large airways. J Allergy Clin Immunol 1998; 101 (3): 386-90
48. Thongngarm T, Silkoff PE, Kossack WS, et al. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma 2005; 42 (4): 257-63
49. Chalupa DC, Morrow PE, OberdorsterG, etal. Ultrafine particle deposition in subjects with asthma. Environ Health Perspect 2004; 112 (8): 879-82
50. Feddah MR, Brown KF, Gipps EM, et al. In vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Pharm Sci 2000; 3 (3): 318-24
51. Leach C, Bethke T, Boudreau R, et al. 2-D and 3-D imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med 2006; 19 (2): 117-26
52. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006; 61 (5): 518-26
53. Engelstaetter R, Steinijans V, Wurst W. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide: results from a pooled analysis [abstract]. Am J Respir Crit Care Med 2004; 169 (7): A92
54. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005; 94 (4): 465-72
55. Drollmann A, Nave R, Steinijans VW, et al. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation. Clin Pharmacokinet 2006; 45: 729-36
56. Bethke TD, Drollmann A, Hauns B, et al. Bioequivalence of two ciclesonide dosing regimen (4 puffs of 200 μg versus 16 puffs of 50 μg using a MDI) [abstract]. Eur Respir J 2002; 20 Suppl. 38: P1914
57. Drollmann A, Bethke TD, Nave R, et al. Bioequivalence of two ciclesonide dosing regimen (4 puffs of 200 μg versus 8 puffs of 100 μg using a MDI) [abstract]. Eur Respir J 2002; 20 Suppl. 38: P1914
58. Nave R, Drollmann A, Steinijans VW, et al. Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin. Int J Clin Pharmacol Ther 2005; 43 (6): 264-70
59. Bohmer G, Drollmann A, Gleiter C, et al. Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmaco-kinetics of ciclesonide and its active metabolite desisobutyryl- ciclesonide. Clin Pharmacokinet 2008; 47 (5): 343-9
60. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998; 101 (4 Pt 2): S440-6
61. Wolthers OD, Honour JW. Measures of hypothalamic-pituitary-adrenal function in patients with asthma treated with inhaled glucocorticoids: clinical and research implications. J Asthma 1999; 36 (6): 477-86
62. Taylor S, Harker A. Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J Pharm Biomed Anal 2006; 41 (1): 299-303
63. Drollmann A, Nave R, Steiner I, et al. Negligible concentration of unbound des-CIC in muscle and subcutaneous adipose tissue after inhalation of ciclesonide in a supra-therapeutic dose [abstract]. Proc Am Thorac Soc 2006; 3 (Abstract Suppl.): A75
64. Derom E, Van DV, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to ade-nosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005; 18 (5): 328-36
65. Lee DK, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005; 127 (3): 851-60
66. Weinbrenner A, Huneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002; 87 (5): 2160-3
67. Szefler S, Rohatagi S, Williams J, et al. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005; 128 (3): 1104-14
68. Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 2005; 115 (5): 940-5
69. Rohatagi S, Krishnaswami S, Pfister M, et al. Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model. Am J Ther 2005; 12 (5): 385-97
70. Nave R, Wingertzahn MA, Brookman S, et al. Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis. J Clin Pharmacol 2006; 46: 461-7
71. Kim K, Weiswasser M, Nave R, et al. Safety of once-daily ciclesonide nasal spray in children with perennial allergic rhinitis. Pediatr Asthma Allergy Immunol 2007; 20 (4): 229-42